April 23, 2024

BeLAB21/22 BRIDGE

BeLAB21/22 BRIDGE
Go back

Mediated and supported by bioRN, Evotec established in 2021 the beLAB2122 BRIDGE. With 20M Euro Fund for preclinical development of academic drug discovery projects, beLAB2122 is a new public-private partnership between the leading academic institutions of the Rhine-Neckar region, Evotec and Bristol Myers Squibb to identify, fund and execute novel disease modifying therapeutic projects with the goal to develop these to new spinout companies.

tester

Our latest News

discover more
AI Diagnoses Brain Tumors in Minutes Instead of Weeks

AI Diagnoses Brain Tumors in Minutes Instead of Weeks

Experts in Heidelberg have developed an AI system that can classify brain tumors with unprecedented accuracy using standard microscopic tissue sections. Using digitized standard stains, the system identifies more than 100 molecular subtypes of central nervous system tumors, delivers results within minutes, and could accelerate the diagnosis of brain tumors worldwide. Tumors of the brain […]

read more
The Heidelberg and Mannheim University Hospitals consortium has taken first place in the Stern hospital rankings

The Heidelberg and Mannheim University Hospitals consortium has taken first place in the Stern hospital rankings

For the first time in 14 years, there has been a change at the top of the hospital rankings, which are published annually by the MINQ Institute in collaboration with Stern. In its very first year of existence, the Heidelberg and Mannheim University Hospitals Consortium has taken first place. More information in German below: Zusammen […]

read more
Presentation of the EY German Biotechnology Report 2026 in Heidelberg: Strong Innovation Ecosystems Are Key to Scaling Innovation

Presentation of the EY German Biotechnology Report 2026 in Heidelberg: Strong Innovation Ecosystems Are Key to Scaling Innovation

Heidelberg, 11 June 2026 – Germany continues to produce world-class science, breakthrough technologies and highly innovative biotechnology companies. However, the challenge is no longer generating innovation – it is creating the conditions that allow innovation to scale. This was one of the central messages emerging from the presentation of the EY German Biotechnology Report 2026, […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp